Showing results (1-10 of 44) with videos related to
Sort By:
Pageof 5
Postgraduate Medicine|July 3, 2013
Comparison of different adjuvant therapies for 9 resectable cancer typesMorgan Kruse, Anju Parthan, John Coombs, et al.Current Medical Research and Opinion|April 18, 2012
Effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumor: results of a population-based, matched-cohort studyHind T Hatoum, Swu-Jane Lin, Medha Sasane, et al.Medicine|June 28, 2024
Clinical and economic burden of medicare beneficiaries with multiple myeloma and renal impairment: An observational studyParameswaran Hari, Dominick Latremouille-Viau, Peggy Lin, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 8, 2024
Critical Comments by Food and Drug Administration Reviewers on Patient-Reported Outcomes in Food and Drug Administration Regulatory Submissions (2018-2021)Christina Slota, Lindsey Norcross, Erin Comerford, et al.BMC Health Services Research|July 11, 2014
Survival, healthcare resource use and costs among stage IV ER + breast cancer patients not receiving HER2 targeted therapy: a retrospective analysis of linked SEER-Medicare dataKathleen Lang, Huan Huang, Medha Sasane, et al.Journal of Medical Economics|November 26, 2014
The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapyAnnie Guerin, Medha Sasane, Genevieve Gauthier, et al.Transfusion|April 11, 2012
Economic impact on US Medicare of a new diagnosis of myelodysplastic syndromes and the incremental costs associated with blood transfusion needStuart L Goldberg, Er Chen, Medha Sasane, et al.The Journal of Emergency Medicine|April 26, 2015
Age-Related Emergency Department Reliance in Patients with Sickle Cell DiseaseMorey A Blinder, Mei Sheng Duh, Medha Sasane, et al.Journal of Medical Economics|September 6, 2012
Long-term persistency and costs associated with the use of iron chelation therapies in the treatment of Sickle cell disease within Medicaid programsEdward P Armstrong, Grant H Skrepnek, Medha Sasane, et al.Journal of Medical Economics|July 6, 2012
Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United StatesMyrlene Sanon, Douglas C A Taylor, Anju Parthan, et al.Pageof 5